26414-90-4

Basic information

• Product Name: 4-Pyridinecarbonitrile, 3-methoxy-
• CAS NO: 26414-90-4
• Molecular Formula: C7H6N2O
• Molecular Weight: 134.137
• Mol File: 26414-90-4.mol

Chemical Properties

• CAS DataBase Reference: 4-Pyridinecarbonitrile, 3-methoxy-(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Pyridinecarbonitrile, 3-methoxy-(26414-90-4)
• EPA Substance Registry System: 4-Pyridinecarbonitrile, 3-methoxy-(26414-90-4)

Safety Data

• Hazardous Substances Data: 26414-90-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Pyridinecarbonitrile, 3-methoxyis used as an intermediate in the synthesis of various drugs and pharmaceutical products for its ability to form heterocyclic compounds, which are essential in creating medications with diverse therapeutic properties.
Used in the Production of Anti-Inflammatory Drugs:
4-Pyridinecarbonitrile, 3-methoxyis used as a building block for the development of anti-inflammatory drugs, contributing to the creation of medications that help reduce inflammation and alleviate pain.
Used in the Production of Anti-Cancer Drugs:
This chemical compound is utilized in the synthesis of anti-cancer drugs, playing a crucial role in the development of medications that target and combat cancer cells.
Used in the Production of Antiviral Drugs:
4-Pyridinecarbonitrile, 3-methoxyis employed in the production of antiviral drugs, aiding in the creation of medications designed to treat and prevent viral infections.
Used as a Reagent in Organic Chemistry Reactions:
In the field of organic chemistry, 4-Pyridinecarbonitrile, 3-methoxyis used as a reagent, facilitating various chemical reactions and contributing to the synthesis of a wide range of compounds.

Upstream product

• 100-48-1 pyridine-4-carbonitrile 
• 68325-15-5 3-chloro-isonicotinonitrile 
• 124-41-4 sodium methylate 

Downstream Products

• 83431-02-1 1-(3-methoxypyridin-4-yl)-ethanone 
• 654663-32-8 3-methoxypyridine-4-carboxylic acid 

Relevant articles and documents

COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES

The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors together with a second compound useful in the treatment of a neurodegenerative disorder and their combined use as a medicament, in particular for the treatment of neurodegenerative and/or cognitive disorders.

1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS

The present invention provides 1H-pyrazolo[4,3-b]pyridines of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.

COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES

The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors together with a second compound which compound is useful in the treatment of a psychiatric disorder and their combined use as a medicament, in particular for the treatment of psychiatric and/or cognitive disorders.

1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS

The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.

FUNCTIONALIZED HETROARYL ENONES EXHIBITING NRF2 ACTIVATION AND THEIR METHOD OF USE

Pharmaceutical compositions are disclosed, which include functionalized hetroaryl enones and are useful for treating or preventing a disease, disorder or condition associated with an NRF2-regulated pathway and/or which involves oxidative stress.

Heterocyclic chalcone activators of nuclear factor (erythroid-derived 2)-like 2 (Nrf2) with improved in vivo efficacy

Nrf2 activators represent a good drug target for designing agents to treat diseases associated with oxidative stress. Building upon previous work, we designed and prepared a series of heterocyclic chalcone-based Nrf2 activators with reduced lipophilicity

3-AMINO-1,5,6,7-TETRAHYDRO-4H-INDOL-4-ONES

Compounds of formula (I) which are inhibitors of Bub1 kinase, processes for their production and their use as pharmaceuticals.

Design, synthesis, and biological evaluation of 17-cyclopropylmethyl-3, 14β-dihydroxy-4,5α-epoxy-6β-[(4′-pyridyl)carboxamido] morphinan derivatives as peripheral selective μ opioid receptor agents

Peripheral selective μ opioid receptor (MOR) antagonists could alleviate the symptoms of opioid-induced constipation (OIC) without compromising the analgesic effect of opioids. However, a variety of adverse effects were associated with them, partially due to their relatively low MOR selectivity. NAP, a 6β-N-4′-pyridyl substituted naltrexamine derivative, was identified previously as a potent and highly selective MOR antagonist mainly acting within the peripheral nervous system. The noticeable diarrhea associated with it prompted the design and synthesis of its analogues in order to study its structure-activity relationship. Among them, compound 8 showed improved pharmacological profiles compared to the original lead, acting mainly at peripheral while increasing the intestinal motility in morphine-pelleted mice (ED50 = 0.03 mg/kg). The slight decrease of the ED50 compared to the original lead was well compensated by the unobserved adverse effect. Hence, this compound seems to be a more promising lead to develop novel therapeutic agents toward OIC.

6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof

Novel 6-heterocyclyl-pyrazolo[3,4-d]pyrimidin-4-ones, useful in treating cardiovascular disease, are prepared by reacting a 5-amino-1H-pyrazole-4-carboxamide with heterocyclylcarboxaldehyde or by reacting a 5-amino-1H-pyrazole-4-carbonitrile with a heterocyclylcarboxamidine, followed by diazotization and hydrolysis of the resulting 4-amino-6-heterocyclyl-pyrazolo[3,4-d]pyrimidine.

Chemoselective Reactions of 3-Chloroisonicotinonitrile

Chemoselective reactions of 3-chloroisonicotinonitrile (1) with nucleophiles are described.Treatment of 1 with sodium methoxide/methanol results in formation of the imino ether, which can be further elaborated into a triazole ring.However, when 1 is react